Low-cost production of recombinant proteins using spERt technology
First written in FY2023. 2 of 3 entries say "Advanced", first in FY2024. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「We promoted the commercialization and advancement of our proprietary spERt® technology, a high-efficiency recombinant protein production system. ... We advanced the development of a foundation for the stable supply and lower-cost production of high-value-added proteins.」
For spERt® technology, production of difficult-to-express proteins, establishment of cell lines and optimization of purification processes were advanced, resulting in progress in building a foundation for stable supply and lower-cost production. - FY2024AdvancedAnnual report
「We manufacture and sell iMatrix-511, a recombinant protein comprising the E8 fragment of human laminin-511. We have introduced the aforementioned spERt technology and switched to manufacturing using cell lines that have achieved higher yields.」
The company introduced spERt technology and switched to producing iMatrix-511 using cell lines that achieved higher yields. Concrete progress toward low-cost, high-efficiency manufacturing was demonstrated. - FY2023First statedAnnual report
「We are advancing the development of spERt technology, an efficient method for producing recombinant proteins, as well as the establishment of CHO cell lines for various proteins and the development of efficient protein purification technologies. We intend to make active use of this technology to improve profitability through the low-cost production of high-value-added proteins.」
spERt technology, aimed at establishing CHO cell lines for recombinant protein production, developing purification technologies and achieving low-cost manufacturing, was identified by name for the first time as an independent means of research and development and earnings improvement.